Previous studies by our group have shown that FGFC1 selectively inhibits erlotinib-resistant non-small cell lung cancer by inhibiting the NF-κB and PI3K/Akt/mTOR pathway-mediated ROS elevation (Feng et al., 2022; Yan et al., 2022). Here, MTOR is linked to non-small cell lung carcinoma.